| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.0027 | 0.9 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | Bexarotene | FIMM | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | NSC632839 | CTRPv2 | pan-cancer | AAC | 0.0019 | 1 |